Bank of Montreal
JNCE

Bank of Montreal’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bank of Montreal’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,853
Closed -$273K – 4003
2021
Q2 		$273K Buy
40,853
+30,184
+283% +$251K ﹤0.01% 3099
2021
Q1 		$111K Sell
10,669
-140,062
-93% -$1.53M ﹤0.01% 3347
2020
Q4 		$1.09M Buy
150,731
+41,670
+38% +$324K ﹤0.01% 2191
2020
Q3 		$1.01M Sell
109,061
-9,013
-8% -$55.9K ﹤0.01% 1981
2020
Q2 		$753K Buy
118,074
+6,199
+6% +$33.4K ﹤0.01% 2065
2020
Q1 		$499K Buy
111,875
+109,638
+4,901% +$631K ﹤0.01% 1985
2019
Q4 		$20K Buy
2,237
+804
+56% +$4.34K ﹤0.01% 4324
2019
Q3 		$5K Sell
1,433
-465
-24% -$1.86K ﹤0.01% 4565
2019
Q2 		$9K Buy
1,898
+1,309
+222% +$6.95K ﹤0.01% 4577
2019
Q1 		$4K Buy
589
+380
+182% +$1.84K ﹤0.01% 4075
2018
Q4 		$1K Buy
209
+4
+2% +$19 ﹤0.01% 4587
2018
Q3 		$2K Sell
205
-3
-1% -$22 ﹤0.01% 4428
2018
Q2 		$2K Buy
+208
New +$3K ﹤0.01% 4431

Other funds holding JNCE

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bank of Montreal's JNCE Position: Q3 2021 in Review

Bank of Montreal sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 40,853 shares — an estimated $273K sold.

Bank of Montreal first reported a position in JNCE in Q2 2018 and held it in 13 quarters. The position peaked at $1.09M in Q4 2020. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

  • Bank of Montreal reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Bank of Montreal sold 40,853 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $273K.
  • Bank of Montreal first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
  • Bank of Montreal's Jounce Therapeutics, Inc. Common Stock position peaked at $1.09M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Bank of Montreal's 13F filing for Q3 2021, filed 12 Nov 2021.